Muhammad Junaid Niaz

MedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer”.

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

The Prostate(2021)10.1002/pros.24104

N/A

1.5DataRank · unranked

27 citations

Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

The Oncologist(2020)10.1634/theoncologist.2020-0028

N/A

0.550DataRank · unranked

38 citations

Jaspreet S. Batra, Ryan D. Walsh, Marigdalia K. Ramirez‐Fort, Shankar Vallabhajosula, Yuliya Jhanwar +6 more

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology(2021)10.3389/fonc.2021.630589

N/A

0DataRank · unranked

43 citations

Muhammad Junaid Niaz, Michael Sun, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.05.028

N/A

0DataRank · unranked

49 citations

Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos +8 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Folate Hydrolase-1 (Folh1) is a Novel Target for Antibody-Based Brachytherapy in Merkel Cell Carcinoma

Skin Health and Disease(2020)10.1002/ski2.9

N/A

0DataRank · unranked

5 citations

Barbara Meier, Kristina Lachance, Sean S. Mahase, Candice D. Church, Muhammad Junaid Niaz +16 more